X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NVG-2089 is a novel, recombinant, non-immunosuppressive immunomodulator designed to target type II Fc receptors and trigger an endogenous regulatory mechanism. It is being developed for the treatment of inflammatory myopathies and severe dermatologic autoimmune disease.
Lead Product(s): NVG-2089
Therapeutic Area: Musculoskeletal Product Name: NVG-2089
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Nuvig is building a pipeline of differentiated protein therapeutics that specifically target affected tissues in a disease-specific manner and can be used in the context of varied but well-defined disease mechanisms.
Lead Product(s): Protein-based Therapeutic
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
